Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Motor Neuron Disease

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Motor Neuron Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FLX 787 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Acronyms COMMEND
  • Sponsors Flex Pharma

    • Most Recent Events

    • 18 Jun 2018 Status changed from active, no longer recruiting to discontinued, because company is ending its ongoing Phase 2 clinical trial investigations of FLX-787 due to oral tolerability concerns observed in a subset of patients being treated for Charcot-Marie-Tooth disease, with the oral disintegrating tablet formulation at 30 mg, taken three times a day, according to a Flex Pharma media release.
    • 13 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 07 Mar 2018 According to a Flex Pharma media release, company expects to report topline results from this study in early 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top